Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CROs And Biopharma Weigh The Balance Of Risk And Responsibility

Executive Summary

Biopharmaceutical companies have been outsourcing R&D activity to CROs for a while, but neither they nor CROs have sorted out which side should bear the burden of what kind of risk and how to best structure operations.


Related Content

Clinical Data In 2014 Could Trigger Private Biotech Financings
J.P. Morgan Notebook: Thursday, January 16
Don’t Call It Outsourcing: Merck Serono’s Broad Deal with Quintiles
Parexel Outlines Biopharma Advances And Increased Outsourcing
No Approval, No Pay: VCs Bet Large On Late-Stage Pharma Trials
When Opportunity Knocks: Eisai Turns To Business Development
Intarcia Forgoes Partnerships, Raises $210M In Equity And Debt Instead
In Advance Of Pharma Partnership, Intarcia Inks Equity Deal With Quintiles


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts